

Freedom of Information Act 2000 - Request Reference FoI/23/049

Anti-VEGF Treatments

Information Requested:

1. For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition:

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab - Ongavia

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab - Ongavia

Response details:

Patients received the following anti-VEGF treatments for any eye condition:

	Sep-22	Oct-22	Nov-22	Dec-22
Aflibercept-Eylea	486	433	484	487
Bevacizumab	0	0	0	0
Brolucizumab	0	0	0	0
Faricimab	0	0	0	0
Ranibizumab - Lucentis	99	106	63	29
Ranibizumab - Ongavia	134	104	136	164
Dexamethasone-Ozurdex	30	14	14	18

Patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

	Sep-22	Oct-22	Nov-22	Dec-22
Aflibercept-Eylea	24	13	13	17
Ranibizumab - Lucentis	0	0	0	0
Ranibizumab - Ongavia	7	2	1	1
Dexamethasone-Ozurdex	0	0	0	0